News

Relmada And REL-1017: Intriguing Underlying Efficacy In MDD Ahead Of Eventful 2024

22 Mins read

Intro

Relmada Therapeutics (NASDAQ:RLMD) is advancing its NMDA antagonist, REL-1017 (esmethadone), as a novel antidepressant for the treatment of major depressive disorder (MDD). After reporting strongly positive Phase 2 results in late 2019, the company announced the failure of two

Read the full article here

Related posts
News

Wall Street Breakfast Podcast: Markets March Higher

2 Mins read
Listen below or on the go on Apple Podcasts and Spotify Stock index futures rise ahead of busy earnings week, inflation data….
News

Mercer Stock Trades For A Price Because Its Financial Risk Is Real And Near (NASDAQ:MERC)

1 Mins read
This article was written by Follow Long-only investment, evaluating companies from an operational, buy-and-hold perspective.Quipus Capital does not focus on market-driven dynamics…
News

Pearson plc (PSO) Q3 2025 Sales Call Transcript

1 Mins read
Unknown Executive Good morning, everyone, and welcome to Pearson’s 2025 9-month Trading Update. [Operator Instructions]. And with that, I’ll hand over to…
Get The Latest News

Subscribe to get the top fintech and
finance news and updates.

Leave a Reply

Your email address will not be published. Required fields are marked *